

Technology Appraisal Committee B Interests Register

Topic: Relugolix for treating hormone-sensitive prostate cancer [ID6187]

Publication Date: 14th August 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Rhiannon Owen	TAC B Committee Member	Financial Interests	Rhiannon acted as a paid consultant to AstraZeneca providing methodological advice for Datopotamab Deruxtecan (Dato-DXd) in HR-positive HER2-negative inoperable or metastatic breast cancer in March 2023.	24/05/2024	It was agreed that Rhiannon's declaration would not prevent her from participating in discussions on this appraisal.
Peter Wheatley Price	TAC B Committee Member	Financial Interests	Takeda manufacture leuprorelin which is a direct competitor to Relugolix	27/05/2024	It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.
David McAllister	TAC B Committee Member	Non-Financial Professional & Personal Interests	Work with data provided by sponsors or their competitors accessed via the Vivli trial data sharing platform.	28/05/2024	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Jonathan Aning	Clinical Expert	Financial Interests	Mr Aning has previously accepted honoraria for advisory boards and teaching / speaking at		It was agreed that Mr Aning's declaration would not prevent him from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			educational events from the following: Accord, Astellas, AstraZeneca, Bayer, Janssen, Merck		providing expert advice to the committee.
Amarnath Challapalli	Clinical Expert	Direct – financial	<p>Speaker Fees: Advanced Accelerator Applications, Astellas, Bayer, BMS, Eisai Ltd, EUSA, Ipsen, Janssen, Novartis, Pfizer, Sanofi</p> <p>Advisory boards: Advanced Accelerator Applications, Merck, Regeneron, Sanofi</p>		It was agreed that Mr Challapalli's declaration would not prevent him from providing expert advice to the committee
		Direct – non-financial	Travel grants for conferences: Astellas, Bayer, EUSA, Ipsen, Janssen, Pfizer, Sanofi		It was agreed that Mr Challapalli's declaration would not prevent him from providing expert advice to the committee
		Indirect	Member of the PCUK Clinical Advisory Group		It was agreed that Mr Challapalli's declaration would not prevent him from providing expert advice to the committee
Stephen Allen	Patient Expert	Direct – non-financial	Tackle Prostate Cancer have provided 2 patient members (Dr Stephen Allen & Mr Andrew Gabriel) to act in an advisory capacity to		It was agreed that Dr Allen's declaration would not prevent him from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Accord Pharmaceuticals. Alongside two oncology consultants they helped design materials to be used as part of structured interviews and an on-line questionnaire commissioned by Accord to act as a patient forum to assess patient views on hormone therapy. The representatives did not have any direct contact with patients participating in these interviews/surveys.</p> <p>as stated above, Stephen was involved directly with Accord in the design of a series of structured patient interviews and an on-line survey/questionnaire concerning hormone therapies.</p>		providing expert advice to the committee